Charles River Laboratories International, Inc. (CRL) reported fourth‑quarter 2025 revenue of $994.2 million, a 0.8% decline from $1,002.5 million in the same period a year earlier. GAAP net loss per diluted share was $5.62, while non‑GAAP earnings per share reached $2.39, beating the consensus estimate of $2.33 by $0.06 (a 2.5% beat). Revenue missed the consensus estimate of $985.92 million by $8.28 million, a 0.8% miss.
The decline in revenue was driven primarily by lower volumes in the Discovery and Safety Assessment (DSA) and Manufacturing segments. In contrast, the Research Models and Services (RMS) segment grew 1.0% to $206.3 million, offsetting some of the weakness in the other two segments. The DSA segment’s improved net bookings in the quarter suggest a stabilizing demand environment, while the Manufacturing segment’s volume contraction reflects broader market softness.
On a non‑GAAP basis, operating margin fell to 18.1% from 19.9% in the prior year, reflecting the impact of lower revenue and higher study‑related direct costs in the DSA segment. Management noted that the company’s cost‑restructuring program has begun to deliver margin benefits, helping to cushion the revenue decline and support the non‑GAAP EPS beat.
Full‑year 2025 results showed total revenue of $4.02 billion and non‑GAAP EPS of $10.28. For 2026, CRL reiterated guidance of flat to +1.5% revenue growth on a reported basis and a non‑GAAP EPS range of $10.70 to $11.20, indicating confidence in a rebound of DSA bookings and continued cost discipline.
James C. Foster, Chair, President and Chief Executive Officer, said, "We were pleased with our 2025 financial results, including substantial improvement in DSA net bookings in the fourth quarter that demonstrates the stabilization of the biopharmaceutical demand environment. We are making significant progress on several strategic initiatives that will enable the Company to better capitalize on future growth opportunities, and we remain intently focused on scientific innovation that will reinforce our position as the leader in preclinical drug development." He added, "Taking these factors into account, cautiously optimistic that favorable DSA demand trends will continue in 2H26 for both DSA segment and CRL overall."
The earnings beat was largely attributed to disciplined cost management and the early impact of the cost‑restructuring program, while the revenue miss reflected weaker volumes in DSA and Manufacturing. Analysts noted that the EPS beat, though modest, signals effective execution, whereas the revenue miss highlights ongoing headwinds in key segments. The guidance for 2026, which maintains flat to modest growth and a higher EPS range, signals management’s confidence in a recovery of DSA demand and continued margin improvement.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.